Jeffrey Humphrey, MD, president, Kyowa Hakko Kirin Pharma, Inc., discusses the benefits of mogamulizumab for the treatment of cutaneous T-cell lymphoma.
Jeffrey Humphrey, MD
Advertisement
Articles by Jeffrey Humphrey, MD
Advertisement
Latest Updated Articles
Dr. Humphrey on Mogamulizumab for Cutaneous T-Cell LymphomaPublished: July 3rd 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5